[go: up one dir, main page]

PA8529501A1 - Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7." - Google Patents

Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."

Info

Publication number
PA8529501A1
PA8529501A1 PA20018529501A PA8529501A PA8529501A1 PA 8529501 A1 PA8529501 A1 PA 8529501A1 PA 20018529501 A PA20018529501 A PA 20018529501A PA 8529501 A PA8529501 A PA 8529501A PA 8529501 A1 PA8529501 A1 PA 8529501A1
Authority
PA
Panama
Prior art keywords
rent
tiadiazols
oxadiazols
optionally replaced
phosphodiesterase
Prior art date
Application number
PA20018529501A
Other languages
English (en)
Inventor
Fabrice Vergne
Pierre Ducrot
Patrick Bernardelli
Charlesa Adrianjara
Edwige Lorthois
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8529501A1 publication Critical patent/PA8529501A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION PROPORCIONA 1,3,4-TIADIAZOLES Y 1,3,4-OXADIAZOLES QUE TIENEN LA SIGUIENTE FORMULA (I):EN DONDE Y ES S U O, R1 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, HETEROCICLOALQUILO, CICLOALQUENILO, ARILO, HETEROARILO O UN GRUPO POLICICLICO, OPTATIVAMENTE SUSTITUIDO, R2 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, HETEROCICLOALQUILO, CICLOALQUENILO O ARILO OPTATIVAMENTE SUSTITUIDO, R3 ES X2-R'3, EN DONDE X2 ES UN GRUPO DE UNION Y R'3 ES CICLOALQUILO, HETEROCICLOALQUILO, CICLOALQUENILO, ARILO, HETEROARILO, O UN GRUPO POLICICLICO, OPTATIVAMENTE SUSTITUIDO, O SUS DERIVADOS FARMACEUTICAMENTE ACEPTABLES,EL PROCESO PARA SU PREPARACION Y SUS USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TRASTORNOS PARA LOS CUALES EL TRATAMIENTO CON UN INHIBIDOR DE PDE7 ES RELEVANTE
PA20018529501A 2000-10-02 2001-09-27 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7." PA8529501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
PA8529501A1 true PA8529501A1 (es) 2003-06-30

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018529501A PA8529501A1 (es) 2000-10-02 2001-09-27 Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."

Country Status (43)

Country Link
US (1) US7122565B2 (es)
EP (2) EP1193261A1 (es)
JP (1) JP4177098B2 (es)
KR (1) KR100614158B1 (es)
CN (1) CN1639141A (es)
AP (1) AP1541A (es)
AR (1) AR035347A1 (es)
AT (1) ATE304003T1 (es)
AU (2) AU2001289945B2 (es)
BG (1) BG107654A (es)
BR (1) BR0114391A (es)
CA (1) CA2424279A1 (es)
CZ (1) CZ2003857A3 (es)
DE (1) DE60113283T2 (es)
DK (1) DK1326853T3 (es)
DZ (1) DZ3440A1 (es)
EA (1) EA007179B1 (es)
EC (1) ECSP034534A (es)
EE (1) EE200300134A (es)
ES (1) ES2247166T3 (es)
GE (1) GEP20053459B (es)
GT (1) GT200100196A (es)
HN (1) HN2001000217A (es)
HR (1) HRP20030247A2 (es)
HU (1) HUP0301248A3 (es)
IL (1) IL155122A0 (es)
IS (1) IS6759A (es)
MA (1) MA25916A1 (es)
MX (1) MXPA03002839A (es)
NO (1) NO20031482D0 (es)
NZ (1) NZ524852A (es)
OA (1) OA12518A (es)
PA (1) PA8529501A1 (es)
PE (1) PE20020419A1 (es)
PL (1) PL366332A1 (es)
PT (1) PT1326853E (es)
SI (1) SI1326853T1 (es)
SK (1) SK3812003A3 (es)
SV (1) SV2003000633A (es)
TN (1) TNSN01139A1 (es)
WO (1) WO2002028847A1 (es)
YU (1) YU24503A (es)
ZA (1) ZA200302346B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
ES2407811T3 (es) 2004-07-01 2013-06-14 Daiichi Sankyo Company, Limited Derivados de tienopirazol que tienen actividad inhibitoria de PDE 7
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
US20180284095A1 (en) * 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (es)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) * 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
WO1999042089A2 (en) * 1998-02-17 1999-08-26 Roche Diagnostics Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives

Also Published As

Publication number Publication date
BG107654A (bg) 2003-12-31
DE60113283D1 (de) 2005-10-13
SK3812003A3 (en) 2004-05-04
DZ3440A1 (fr) 2002-04-11
CA2424279A1 (en) 2002-04-11
GEP20053459B (en) 2005-02-25
KR100614158B1 (ko) 2006-08-21
OA12518A (en) 2006-05-29
CN1639141A (zh) 2005-07-13
EP1326853A1 (en) 2003-07-16
HUP0301248A3 (en) 2005-06-28
US7122565B2 (en) 2006-10-17
ZA200302346B (en) 2004-08-04
PE20020419A1 (es) 2002-07-18
KR20030068542A (ko) 2003-08-21
TNSN01139A1 (en) 2005-11-10
EP1326853B1 (en) 2005-09-07
HN2001000217A (es) 2002-06-13
WO2002028847A1 (en) 2002-04-11
JP2004510769A (ja) 2004-04-08
HRP20030247A2 (en) 2005-04-30
YU24503A (sh) 2006-03-03
AP1541A (en) 2006-01-11
DK1326853T3 (da) 2005-12-12
ES2247166T3 (es) 2006-03-01
AU8994501A (en) 2002-04-15
SI1326853T1 (sl) 2005-12-31
IL155122A0 (en) 2003-10-31
GT200100196A (es) 2002-07-18
AU2001289945B2 (en) 2005-12-22
MA25916A1 (fr) 2003-10-01
AR035347A1 (es) 2004-05-12
CZ2003857A3 (cs) 2004-02-18
IS6759A (is) 2003-03-27
EA200300333A1 (ru) 2003-10-30
EA007179B1 (ru) 2006-08-25
EP1193261A1 (en) 2002-04-03
ECSP034534A (es) 2003-07-25
BR0114391A (pt) 2003-06-24
HUP0301248A2 (hu) 2003-10-28
ATE304003T1 (de) 2005-09-15
MXPA03002839A (es) 2004-09-10
JP4177098B2 (ja) 2008-11-05
NO20031482L (no) 2003-04-01
PL366332A1 (en) 2005-01-24
DE60113283T2 (de) 2006-06-08
NZ524852A (en) 2004-09-24
EE200300134A (et) 2003-08-15
US20030045557A1 (en) 2003-03-06
PT1326853E (pt) 2005-11-30
NO20031482D0 (no) 2003-04-01
AP2003002764A0 (en) 2003-03-31
SV2003000633A (es) 2003-04-03

Similar Documents

Publication Publication Date Title
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
ECSP034914A (es) "azaindoles"
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
PT1263724E (pt) Novos compostos
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ECSP034922A (es) Pirrolopirimidinas
IS6658A (is) Ný efnasambönd
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DE60121461D1 (de) Kondensierte pyridoindolderivate
IT1312115B1 (it) Composti amorfi e relative composizioni farmaceutiche
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
SE0102055D0 (sv) New Compounds
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
AR026350A1 (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa vii
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE